These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
523 related items for PubMed ID: 30232824
1. Paclitaxel-eluting balloon versus everolimus-eluting stent in patients with diabetes mellitus and in-stent restenosis: Insights from the randomized DARE trial. Claessen BE, Henriques JPS, Vendrik J, Boerlage-van Dijk K, van der Schaaf RJ, Meuwissen M, van Royen N, Gosselink ATM, van Wely MH, Dirkali A, Arkenbout EK, Piek JJ, Baan J. Catheter Cardiovasc Interv; 2019 Feb 01; 93(2):216-221. PubMed ID: 30232824 [Abstract] [Full Text] [Related]
2. Long-term outcomes after treatment of bare-metal stent restenosis with paclitaxel-coated balloon catheters or everolimus-eluting stents: 3-year follow-up of the TIS clinical study. Pleva L, Kukla P, Zapletalova J, Hlinomaz O. Catheter Cardiovasc Interv; 2018 Nov 15; 92(6):E416-E424. PubMed ID: 30019843 [Abstract] [Full Text] [Related]
4. 3-Year Clinical Follow-Up of the RIBS IV Clinical Trial: A Prospective Randomized Study of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis in Coronary Arteries Previously Treated With Drug-Eluting Stents. Alfonso F, Pérez-Vizcayno MJ, Cuesta J, García Del Blanco B, García-Touchard A, López-Mínguez JR, Masotti M, Zueco J, Cequier A, Velázquez M, Moreno R, Mainar V, Domínguez A, Moris C, Molina E, Rivero F, Jiménez-Quevedo P, Gonzalo N, Fernández-Pérez C, RIBS IV Study Investigators (Under the Auspices of the Interventional Cardiology Working Group of the Spanish Society of Cardiology). JACC Cardiovasc Interv; 2018 May 28; 11(10):981-991. PubMed ID: 29798776 [Abstract] [Full Text] [Related]
5. Efficacy of a seal-wing paclitaxel-eluting balloon catheters in the treatment of bare metal stent restenosis. Pleva L, Kukla P, Zapletalova J, Hlinomaz O. BMC Cardiovasc Disord; 2017 Jun 26; 17(1):168. PubMed ID: 28651572 [Abstract] [Full Text] [Related]
6. Long-Term Results of Everolimus-Eluting Stents Versus Drug-Eluting Balloons in Patients With Bare-Metal In-Stent Restenosis: 3-Year Follow-Up of the RIBS V Clinical Trial. Alfonso F, Pérez-Vizcayno MJ, García Del Blanco B, Otaegui I, Masotti M, Zueco J, Veláquez M, Sanchís J, García-Touchard A, Lázaro-García R, Moreu J, Bethencourt A, Cuesta J, Rivero F, Cárdenas A, Gonzalo N, Jiménez-Quevedo P, Fernández C, RIBS V Study Investigators. JACC Cardiovasc Interv; 2016 Jun 27; 9(12):1246-1255. PubMed ID: 27339840 [Abstract] [Full Text] [Related]
7. Comparison of the Efficacy of Paclitaxel-Eluting Balloon Catheters and Everolimus-Eluting Stents in the Treatment of Coronary In-Stent Restenosis: The Treatment of In-Stent Restenosis Study. Pleva L, Kukla P, Kusnierova P, Zapletalova J, Hlinomaz O. Circ Cardiovasc Interv; 2016 Apr 27; 9(4):e003316. PubMed ID: 27069104 [Abstract] [Full Text] [Related]
8. Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials. Alfonso F, Pérez-Vizcayno MJ, García Del Blanco B, García-Touchard A, López-Mínguez JR, Masotti M, Zueco J, Melgares R, Mainar V, Moreno R, Domínguez A, Sanchís J, Bethencourt A, Moreu J, Cequier A, Martí V, Otaegui I, Bastante T, Gonzalo N, Jiménez-Quevedo P, Cárdenas A, Fernández C, under the auspices of the Interventional Cardiology Working Group of the Spanish Society of Cardiology. Circ Cardiovasc Interv; 2016 Jul 27; 9(7):. PubMed ID: 27412868 [Abstract] [Full Text] [Related]
9. Drug-Eluting Balloons Versus Everolimus-Eluting Stents for In-Stent Restenosis: A Meta-Analysis of Randomized Trials. Elgendy IY, Mahmoud AN, Elgendy AY, Mojadidi MK, Elbadawi A, Eshtehardi P, Pérez-Vizcayno MJ, Wayangankar SA, Jneid H, David Anderson R, Alfonso F. Cardiovasc Revasc Med; 2019 Jul 27; 20(7):612-618. PubMed ID: 30126824 [Abstract] [Full Text] [Related]
10. Long-Term Efficacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis: 3-Year Results of a Randomized Controlled Trial. Kufner S, Cassese S, Valeskini M, Neumann FJ, Schulz-Schüpke S, Hoppmann P, Fusaro M, Schunkert H, Laugwitz KL, Kastrati A, Byrne RA, ISAR-DESIRE 3 Investigators. JACC Cardiovasc Interv; 2015 Jun 27; 8(7):877-84. PubMed ID: 26003022 [Abstract] [Full Text] [Related]
11. Two-year results and subgroup analyses of the PEPCAD China in-stent restenosis trial: A prospective, multicenter, randomized trial for the treatment of drug-eluting stent in-stent restenosis. Xu B, Qian J, Ge J, Wang J, Chen F, Chen J, Wei M, Chen Y, Yang Y, Gao R, PEPCAD China ISR investigators. Catheter Cardiovasc Interv; 2016 Mar 27; 87 Suppl 1():624-9. PubMed ID: 26775079 [Abstract] [Full Text] [Related]
12. Bioresorbable vascular scaffold versus everolimus-eluting stents or drug eluting balloon for the treatment of coronary in-stent restenosis: 1-Year follow-up of a propensity score matching comparison (the BIORESOLVE-ISR Study). Moscarella E, Tanaka A, Ielasi A, Cortese B, Coscarelli S, De Angelis MC, Piraino D, Latib A, Grigis G, Bianchi R, Buccheri D, Calabrò P, Tespili M, Silva Orrego P, Colombo A, Varricchio A. Catheter Cardiovasc Interv; 2018 Oct 01; 92(4):668-677. PubMed ID: 29356269 [Abstract] [Full Text] [Related]
14. Long-Term Outcomes After Treatment With a Paclitaxel-Coated Balloon Versus Balloon Angioplasty: Insights From the PEPCAD-DES Study (Treatment of Drug-eluting Stent [DES] In-Stent Restenosis With SeQuent Please Paclitaxel-Coated Percutaneous Transluminal Coronary Angioplasty [PTCA] Catheter). Rittger H, Waliszewski M, Brachmann J, Hohenforst-Schmidt W, Ohlow M, Brugger A, Thiele H, Birkemeyer R, Kurowski V, Schlundt C, Zimmermann S, Lonke S, von Cranach M, Markovic S, Daniel WG, Achenbach S, Wöhrle J. JACC Cardiovasc Interv; 2015 Nov 01; 8(13):1695-700. PubMed ID: 26476609 [Abstract] [Full Text] [Related]